Maruho Launches In Vitro Diagnostic "DermaQuick® VZV"
Osaka (Japan), January 22, 2018 - Maruho Co., Ltd ("Maruho", Head Office: Osaka, Japan, President and CEO: Koichi Takagi) announces it launched in vitro diagnostic (varicella-zoster virus antigen kit), (Brand name: "DermaQuick® VZV", hereinafter referred to as "the product"), in Japan today.
The product is the first varicella-zoster virus (hereinafter VZV) antigen kit in the world with immunochromatography as the principle measurement. From a sample of skin rash, or a swab of a sore/ulcer fluid, it is possible to detect VZV antigens conveniently and rapidly in 5 to 10 minutes.
Maruho received manufacturing and marketing approval for the product on June 27, 2017, and examinations using the product received insurance coverage on August 7, 2017.
Maruho markets oral and topical therapeutic treatments for herpes zoster (shingles) as prescription drugs. By expanding our business to cover the entire care cycle (prevention, examination/diagnosis, treatment, and after care), Maruho is working to meet a wide range of patient needs at every stage of care.
Product Profile:
Brand Name | DermaQuick® VZV |
Nonproprietary Name | Varicella-zoster virus antigen kit |
Target Use | Detection of varicella-zoster virus antigen in a sample of skin rash (blister/pustule) or a swab of a sore/ulcer fluid (including epithelial cells). (To be used mainly for diagnosis of varicella-zoster virus infection). |
Packaging | 10 kits per box |
Suggested Retail Price | 24,000 yen |
Date of Launch | January 22, 2018 |
Manufacturer | Maruho Co., Ltd. |
Insurance Coverage Profile
In Vitro Diagnostic Name | Varicella-zoster virus antigen kit |
Date of Insurance Coverage | August 7, 2017 |
NHI Service Points | Varicella virus antigen qualitative analysis (epithelial cells) 240 points |
NHI Diagnosis Points | Immunological examination diagnosis fee 144 points |
Product Photo